Evidence map›Paper›PMID 33963913›Full record

ArticleInternational journal of colorectal disease2021

Profile of patients with inflammatory bowel disease in conjunction with unmet needs and decision-making for choosing a new biologic therapy: a baseline analysis of the VEDO

Romina di Giuseppe, Sandra Plachta-Danielzik, Wolfgang Mohl, Martin Hoffstadt, Thomas Krause, Bernd Bokemeyer, Stefan Schreiber

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of colorectal disease, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Romina di GiuseppeKompetenznetz Darmerkrankungen, Kiel, Germany.
Sandra Plachta-DanielzikKompetenznetz Darmerkrankungen, Kiel, Germany.
Wolfgang MohlGastroenterology Practice, Saarbrücken, Germany.
Martin HoffstadtGastroenterology Practice, Iserlohn, Germany.
Thomas KrauseGastroenterology Practice, Kassel, Germany.
Bernd BokemeyerKompetenznetz Darmerkrankungen, Kiel, Germany. bernd.bokemeyer@t-online.de.
Stefan SchreiberKompetenznetz Darmerkrankungen, Kiel, Germany.
Kompetenznetz Darmerkrankungen · DEKlinikum Saarbrücken · DEMedice (Germany) · DEVitos Orthopedic Clinic Kassel · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeWe characterized the profile of Crohn's disease (CD) or ulcerative colitis (UC) biologic-naïve patients (starting a new therapy with vedolizumab or TNFα-antagonists), their baseline disease activity predictors, and their perception of the quality of life (HRQoL).

methodsThe VEDO

resultsWhen compared to biologic-naïve anti-TNF patients, a first biological therapy with vedolizumab was considered for older CD patients, with a less complicated though longer disease course, and with a history of comorbidities. No differences in (unmet) needs were observed among patients with UC. The presence of extra-intestinal manifestations in biologic-naïve anti-TNF patients with CD (OR (95% CI): 3.83 (1.69-8.68)) and, in both biologic-naïve groups of patients with UC, stool frequency (2.00 (1.25-3.19); 1.82 (1.10-3.02), respectively) and rectal bleeding (2.24 (1.20-4.18); 1.92 (1.19-3.11), respectively) emerged as the most important predictors of disease severity, which in turn were also significantly associated with a worse HRQoL.

conclusionThis study highlights the existence of unmet medical needs of patients with CD or UC, for whom a new biological therapy is planned as part of the VEDO

Indexed as

Colitis, UlcerativeInflammatory Bowel DiseasesBiological TherapyGastrointestinal AgentsHumansQuality of LifeRemission InductionTumor Necrosis Factor InhibitorsGastrointestinal AgentsTumor Necrosis Factor InhibitorsBiologicsDecision-makingPredictorsReal-world dataVedolizumab

Identifiers

PMID33963913
OpenAlexW3158538238

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.